Revvity Secures $15 Million in Funding: Oxford Immunotec Embraces a New Era

Oxford Immunotec, now rebranded as Revvity, is thrilled to announce the successful completion of a $15 million funding round aimed at accelerating the development of its innovative diagnostic solutions. As a pioneering leader in the field of immunology and infectious disease diagnostics, Revvity specializes in delivering precise and rapid testing solutions that inform effective patient care decisions. This crucial funding will be instrumental in advancing the company’s product pipeline, enhancing research capabilities, and expanding its market reach. With these resources, Revvity plans to invest in the development of next-generation technologies that leverage cutting-edge techniques to improve diagnostic accuracy and speed, ultimately empowering healthcare providers to deliver timely and informed treatment options. The funding comes on the heels of a strategic transformation that has positioned Revvity as a forward-thinking player in the diagnostics landscape. As the company embarks on this exciting new phase, it remains committed to its mission of advancing public health by providing unparalleled diagnostic insights. For more details about our evolution and future goals, we invite you to visit our transformation update page at update.oxfordimmunotec.com/transformation. Revvity is ready to tackle the challenges of tomorrow with innovative solutions that will make a lasting impact in the healthcare community. This significant boost in funding not only enhances our operational capabilities but also strengthens our commitment to improving patient outcomes worldwide. Stay tuned as we continue to chart our course in transforming diagnostics for the better.